# Hoffmann-La Roche: Phase 3 study closed enrollment, 451 enrolled (Neovascular Age-related Macular Degeneration (nAMD))

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) |
| NCT ID | NCT04657289 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Neovascular Age-related Macular Degeneration (nAMD) |
| Intervention types | drug, device |
| Target enrollment | 451 |
| Site countries | Argentina, Australia, Austria, Belgium, Brazil, France, Germany, Israel, Italy, Singapore, South Korea, Spain |
| Posted | 2020-12-08 |
| Planned start | 2021-07-14 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-29 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 451 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04657289). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.